Criteria of response was never going to be attainable in these late stage patients the anti leukaemia responses are what shows the possible advantage of treating patients who are not at such a late stage. You never pointed that sentence out or the blast count reduction, you cherry picked the results to back up your negatively exaggerated analysis. You are shameless. Imo
- Forums
- ASX - By Stock
- SPL
- Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-162
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $41.73M |
Open | High | Low | Value | Volume |
9.9¢ | 10.5¢ | 9.9¢ | $49.15K | 486.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 65751 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 226460 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 65751 | 0.100 |
2 | 107649 | 0.099 |
1 | 300000 | 0.098 |
2 | 45155 | 0.097 |
2 | 100000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 226460 | 3 |
0.110 | 240068 | 5 |
0.115 | 109827 | 3 |
0.120 | 63057 | 7 |
0.125 | 80424 | 5 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |